Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer Taking Over Actimis In Structured Buyout

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal worth up to $515 million brings Phase I asthma therapy.

You may also be interested in...

GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund

The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.

Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio

TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline

Astellas' Out-Licensing Deal With Cardeus Could Be Model For Development Outsourcing Of More Of Its Portfolio

Astellas has looked to outsource some development programs with "satellite companies" and believes the solution may rest with small startups.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts